BTL, a global leader in advanced medical technologies, is thrilled to announce that Emsculpt Neo has received a new FDA clearance for use in stimulating neuromuscular tissue for bulk muscle excitation in the legs or arms for rehabilitative purposes. The Emsculpt's groundbreaking technology revolutionized the body contouring market in 2020 by combining fat reduction and muscle building in one treatment. In 2024, the Emsculpt Neo is set to expand into the wellness market by addressing various medical conditions and further improving patients' quality of life.

Emsculpt Neo is now cleared for:

• Prevention or retardation of disuse atrophy
• Muscle re-education
• Maintaining or increasing range of motion
• Immediate post-surgical prevention of calf muscles to prevent venous thrombosis
• Relaxation of muscle spasms
• Increasing local blood circulation

"Emsculpt Neo not only enhances patients' satisfaction with physical appearance but also improves how they feel and function," said Dr. Mohamed Abdulhamid. "The newfound capabilities of Emsculpt Neo have transformed my patients' lives in ways I never thought possible. After years of struggling with muscle weakness post-surgery, they regained strength and mobility that traditional therapy couldn't provide. Seeing them walk confidently again was truly life-changing."

The market potential for Emsculpt Neo is vast, catering to:

• Post-surgery and rehabilitation patients
• Individuals seeking increased mobility & flexibility
• Active elderly combating age-related deterioration
• Recreational athletes aiming to prevent injuries
• Professional athletes experiencing joint and muscle overload

With over 4 million treatments performed to date, Emsculpt Neo remains the gold standard in body sculpting, delivering unparalleled results for muscle building and fat reduction.

"This FDA clearance opens up new frontiers and possibilities for Emsculpt Neo as a platform that continues to evolve, bringing new patients to practices," said Rohit Mishra, Director of Product Management. "We are committed to innovation that meets the changing needs of our customers, and this advancement reinforces our dedication to excellence in both the aesthetic and medical fields."

David Chmel, CEO of BTL Industries, added, "The rising demand for our treatments and the continued success of the Emsculpt Neo franchise highlights our strong position as we anticipate further growth into Q4 2024 and 2025."

For more information about Emsculpt Neo, please visit emsculptneo.com.

About BTL

Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 500 in-house engineers, BTL leverages technology and science to advance medical treatments. Its product portfolio includes EMSCULPT NEO®, EMFACE®, EXION™, EMSELLA®, and others. For more information, visit www.bodybybtl.com

CONTACT: btlaesthetics@nouveaucommunications.com

BTL, a global leader in advanced medical technologies, is proud to announce the launch of Clear RF™, the latest innovation for the BTL Exion™ multiplatform system. Exion Clear RF harnesses advanced radio frequency microablation technology to address skin tone, texture, and skin discoloration concerns. This cutting-edge technology is designed to deliver more precise and effective outcomes across various patient profiles and is suitable for use in multiple medical specialties.

Clear RF stands out due to its incorporation of Smart Microablation technology that ensures homogeneous microablation with each pulse, increasing precision and ease of use without unnecessary skin damage. This technology makes Clear RF a game-changer in skin health treatments, allowing providers to maximize consistency and deliver personalized treatments for their patients.

"Clear RF represents a breakthrough in this type of technology, offering standalone value to our clients while seamlessly integrating with the Exion™ multiplatform system," said Daniel Zenker, Director of Product Management at BTL. "By incorporating Clear RF into the Exion system, medical practitioners across specialties can enhance patient outcomes and offer specialized treatments tailored to the unique needs of every patient."

Lesley Clark-Loeser from Precision Skin Institute in Davie FL stated "This really does round out the platform because it allows for us to treat issues of pigmentation, various vascular concerns, texture, tone and overall quality of the skin in quite an amazing way. It is well tolerated by my patients. Clear RF can be done as a standalone procedure, or combined with other applicators on the EXION platform."

Clear RF represents BTL's commitment to advancing medical treatments through innovation and delivering unparalleled results for both providers and patients.

For more information about Clear RF and the Exion multiplatform system, visit www.exion.com.

About BTL Industries

Established in 1993, BTL has become a global leader in the medical device industry, providing innovative solutions across a wide range of medical specialties. With a team of over 3,700 employees in more than 80 countries, BTL supports healthcare professionals in fields such as dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and many others. BTL's portfolio of brands includes EMSCULPT® and EMSCULPT NEO®, EMFACE®, BTL EXION™, EMSELLA® and EMTONE®. For more information, please visit www.bodybybtl.com.

BTL Industries, a global leader in medical devices for wellness, aesthetics, and longevity, is pleased to announce its strategic partnership with JANZ Corporation, a renowned medical equipment provider and supplies to U.S. Government healthcare facilities and clinics. This collaboration aims to deliver cutting-edge solutions to enhance the physical strength and well-being of U.S. military personnel and veterans.

JANZ Corporation is recognized for its extensive range of medical supplies, catering to the needs of active U.S. military bases and specialized VA facilities. Their robust contract portfolio simplifies the procurement process for government purchasing agents, ensuring timely and efficient access to necessary medical products.

Through this partnership, BTL Industries will offer its revolutionary Emsculpt Neo technology to military and veteran communities via JANZ Corporation. Emsculpt Neo, renowned for strengthening, toning, and firming the muscles and eliminating fat, will be utilized to enhance physical performance, improve body composition, and strengthen muscles, thereby reducing the risk of injury in combat and improving the quality of life. Furthermore, this innovative technology offers both proactive and corrective treatment options for those who want to build or strengthen their muscles. Based on several clinical studies, this device has demonstrated its ability to build muscle by 25% and reduce fat by 30%*. As veterans age, maintaining muscle mass, mobility, and balance becomes more challenging. The Emsculpt NEO can help with age-related muscle loss, improved balance, and mobility, promoting a healthier and more active lifestyle for aging veterans. The machine's versatility in treating different parts of the body, such as the abdomen, arms, legs, and buttocks, makes it suitable for veterans who may have difficulties building muscles in certain areas due to debilitating injuries, helping them maintain peak physical condition and performance.

"Providing Strength to Those That Serve" is at the heart of this collaboration. BTL Industries and JANZ Corporation are dedicated to supporting the health and well-being of those who serve the nation, offering them top-tier medical solutions. David Chmel, CEO of BTL Industries, stated, "We are thrilled to partner with JANZ Corporation to bring our advanced Emsculpt NEO technology to those who have dedicated their lives to serving our country. This partnership highlights our dedication to enhancing the health and well-being of military personnel and veterans, equipping them with the resources they need to stay in the best physical shape."

About BTL Industries Founded in 1993, BTL has grown to become one of the world's leading medical and aesthetic equipment manufacturers. With over 3,500 employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including women's intimate health and wellness. BTL's brands include EMSCULPT NEO®, EMFACE®, EMSCULPT®, EMSELLA®, EMTONE®, EMFEMME 360™, EXION™, and Core to Floor®, as well as their proprietary HIFEM® and HIFES™. For additional information, please visit www.bodybybtl.com.

BTL Industries, Inc., a leading provider of innovative medical aesthetic solutions, petitioned the U.S. Patent Office to cancel all 58 claims of U.S. Patent No. 8,961,511 owned by the company InMode Ltd.

"We have strong reasons to believe InMode's patent claims are invalid," explained David Chmel, BTL's CEO, "and BTL has asked the United States Patent Office to initiate invalidation proceedings."

For more information about BTL and its medical solutions, please visit www.bodybybtl.com.

ABOUT BTL
Founded in 1993, BTL has grown to become one of the world's leading medical and aesthetic equipment manufacturers. With over 3,500 employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including women's intimate health and wellness. BTL's brands include EMSCULPT NEO^®, EMFACE^®,  EMSCULPT^®, EMSELLA^®, EMTONE^®, EMFEMME 360™, EXION™, and Core to Floor^®, as well as their proprietary HIFEM^® and HIFES™. Please visit www.bodybybtl.com for additional information. 

BTL Industries, a renowned leader in cutting-edge medical technologies, is excited to announce its participation in the upcoming American Society for Laser Medicine and Surgery (ASLMS) Conference, taking place from April 11 to April 14, 2024, in Baltimore, Maryland. This prestigious event brings together top experts, researchers, and practitioners in the field of medical laser applications and energy-based treatments.

BTL Industries is set to unveil its latest advancements in aesthetic and muscle enhancement at ASLMS, redefining possibilities for enhancing both form and function. With a commitment to innovation and excellence, BTL Industries continues to pave the way for transformative outcomes in medical technology, empowering healthcare professionals to deliver unparalleled solutions for diverse patient needs.

Highlighted below are the presentations featuring BTL Industries' groundbreaking products and technologies:

EMFACE

• Five oral presentations
• Topics include tackling challenging submentum cases with Emface, combination technique for Botulinum toxins and Emface treatments, histologic and clinical evaluation of Emface on submentum, facial rejuvenation and volumization with Emface, and facial lifting in Asian population
• E-Poster on the combination of injectables and Emface

EMSCULPT NEO

• Three oral presentations
• Topics include core strength in moms and seniors, muscle stimulation for functional enhancement, and obtaining an hourglass figure noninvasively

EMSELLA

• Oral presentation
• Topics include enhancing the quality of life in elderly men with post-prostatectomy incontinence.

Commenting on BTL Industries' leadership position in muscle stimulation technologies for enhancing both form and function, Rohit Mishra, Director of Product Management at BTL Industries, stated: "We are proud to lead the way in advancing the application of muscle stimulation techniques for optimizing both appearance and quality of life. Our commitment to research and development enables us to continuously push the boundaries of innovation, providing healthcare professionals with unparalleled tools to enhance patient outcomes and satisfaction."

BTL Industries looks forward to engaging with attendees, sharing insights, and fostering collaboration to drive further advancements in medical laser technology and energy-based therapies.

The American Society for Laser Medicine and Surgery Inc. (ASLMS) has the ultimate responsibility for the planning, development and content of continuing education programs and presentations, including those highlighted above. BTL did not direct content or influence the planning or implementation of the ASLMS 43^rd  Annual Conference. The spontaneous opinions expressed by speakers and participants during these activities belong to those individuals.

About BTL Industries:

Founded in 1993, BTL has grown to become one of the world's leading medical and aesthetic equipment manufacturers. With over 3,500 employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including women's intimate health and wellness. BTL's brands include EMSCULPT NEO^®, EMFACE^®,  EMSCULPT^®, EMSELLA^®, EMTONE^®, EMFEMME 360™, EXION™, and Core to Floor^®, as well as their proprietary HIFEM^® and HIFES™. Please visit www.bodybybtl.com for additional information. 

In a grand celebration of its most successful year, BTL, a pioneer in the medical aesthetics industry, hosted its largest national sales meeting yet. This marked a significant milestone for the company, having reached a record revenue of 680 million USD in 2023. The event was not just a commemoration of past achievements but also a stage for groundbreaking innovations. The spotlight was on the introduction of the new EMFACE Submentum applicator, a device poised to revolutionize the treatment of double chins.

BTL's technological prowess is long-established, and this addition to the EMFACE platform represents a new flagship in BTL's journey. Harnessing the power of patented Synchronized RF+ and HIFES™ technology for facial muscle stimulation, the EMFACE stands as the most innovative non-invasive procedure in the industry.

David Chmel, BTL's CEO, expressed his vision and confidence in the new product. "EMFACE is not just an innovation for today; it lays the foundation for future advancements. By focusing on new treatment areas, we ensure that our technological advancements continue to add value for our customers and redefine the industry."

Designed to prioritize patient comfort, the EMFACE Submentum applicator offers a needle-free and bruise-free treatment. Its noninvasive technology uniquely targets layers from skin to muscle, enhancing the aesthetic appearance with unprecedented precision and ease.

Jennifer Levine, MD, a renowned New York City-based facial plastic surgeon, shared her enthusiasm for EMFACE's potential. "The EMFACE represents a revolution in double-chin treatments. We now have the ability to target the deeper structures non-invasively in a safe and effective manner."

For more information about the Emface applicator and other innovative products from BTL, please visit emface.com.

About BTL:
Founded in 1993, BTL has grown to become one of the world's leading medical and aesthetic equipment manufacturers. With over 3,000 employees in over 80 countries, BTL offers advanced non-invasive solutions for body-shaping, skin-tightening, and other medical aesthetic treatments, including women's intimate health and wellness. BTL's brands include EMSCULPT NEO^®, EMFACE^®,  EMSCULPT^®, EMSELLA^®, EMTONE^®, EMFEMME 360™, EXION™, and Core to Floor^®, as well as their proprietary HIFEM^® and HIFES™. Please visit www.bodybybtl.com for additional information.